HRTX — Heron Therapeutics Cashflow Statement
0.000.00%
- $527.29m
- $605.30m
- $127.04m
- 40
- 25
- 88
- 49
Annual cashflow statement for Heron Therapeutics, fiscal year end - December 31st, USD millions except per share, conversion factor applied.
2019 December 31st | 2020 December 31st | 2021 December 31st | 2022 December 31st | 2023 December 31st | |
---|---|---|---|---|---|
Period Length: | 12 M | 12 M | 12 M | 12 M | 12 M |
Source: | 10-K | 10-K | 10-K | 10-K | 10-K |
Standards: | USG | USG | USG | USG | USG |
Status: | Final | Final | Final | Final | Final |
Net Income/Starting Line | -205 | -227 | -221 | -182 | -111 |
Depreciation | |||||
Non-Cash Items | 48.9 | 52.6 | 49.4 | 42.7 | 32.1 |
Unusual Items | |||||
Other Non-Cash Items | |||||
Changes in Working Capital | 29.2 | -13 | -35.1 | -10.5 | 16.8 |
Change in Accounts Receivable | |||||
Change in Inventories | |||||
Change in Prepaid Expenses | |||||
Change in Accounts Payable | |||||
Change in Accrued Expenses | |||||
Cash from Operating Activities | -125 | -185 | -203 | -147 | -58.8 |
Capital Expenditures | -7.15 | -6.81 | -3.02 | -1.82 | -1.54 |
Purchase of Fixed Assets | |||||
Other Investing Cash Flow Items | -14.6 | 216 | 35.8 | -1.5 | 19.5 |
Sale of Fixed Assets | |||||
Sale/Maturity of Investment | |||||
Purchase of Investments | |||||
Cash from Investing Activities | -21.8 | 209 | 32.7 | -3.32 | 18 |
Financing Cash Flow Items | — | 0.026 | — | — | — |
Other Financing Cash Flow | |||||
Net Issuance / Retirement of Stock | |||||
Net Issuance / Retirement of Debt | |||||
Cash from Financing Activities | 186 | 9.11 | 156 | 75.1 | 54.1 |
Beginning Cash Balance | |||||
Ending Cash Balance | |||||
Net Change in Cash | 40.1 | 33.2 | -14.6 | -75.2 | 13.3 |